normalization of serum pSa level using zoledronic acid on metastatic hormone-refractory prostate cancer resistant to estramustine and betamethasone

Abstract

We present a 78-year-old male with hormone-refractory prostate cancer (HRPC), who obtained complete long term regression of prostate specific antigen level during zoledronic acid (ZA) therapy. Our case suggests clinical utility of ZA in managing some of HRPC patients.